Market Research Logo

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

About non-small cell lung cancer therapeutics

Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is considered as a major cause of lung cancer, although lung cancer also occurs in non-smokers. There are three main types of non-small cell lung cancer: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Some of the common symptoms associated with non-small cell lung cancer are chest pain, a cough that does not go away, coughing up blood, fatigue, loss of appetite, losing weight without trying, shortness of breath, and wheezing.

Technavio's analysts forecast the global non-small cell lung cancer therapeutics market to grow at a CAGR of 6.77% over the period 2014-2019.

Covered in this report

The report covers the current scenario and the growth prospects of the global non-small cell lung cancer therapeutics market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used for the treatment of non-small cell lung cancer.

Technavio's report, Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and Europe; it also covers the landscape of the global non-small cell lung cancer therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • Europe
Key vendors
  • AstraZeneca
  • Celgene
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Pfizer
Other prominent vendors
  • Abbvie
  • Aetna
  • Agennix
  • Amgen
  • BetaPharma
  • Bionumerik Pharmaceuticals
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CBT Pharma
  • Celldex Therapeutics
  • Dainippon Pharma
  • Eisai Pharmaceuticals
  • GlaxoSmithKline
  • Helsinn
  • IMClone Systems
  • IsisPharma
  • Kadmon
  • Kyowa Hakko Kirin
  • MabVax Therapeutics
  • Merck
  • Novartis
  • OncoGenex
  • OSI Pharmaceuticals
  • Peregrine
  • Pierre Fabre
  • Qiagen
  • Sanofi
  • Synta Pharmaceuticals
  • Teva Pharmaceuticals
Key market driver
  • Promising drug pipeline
  • For a full, detailed list, view our report
Key market challenge
  • High cost of therapy
  • For a full, detailed list, view our report
Key market trend
  • Personalized medicine
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Non-Small Cell Lung Cancer Therapeutics Market: AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche, and Pfizer.

Other Prominent Vendors in the market are: Abbvie, Aetna, Agennix, Amgen, BetaPharma, Bionumerik Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, CBT Pharma, Celldex Therapeutics, Dainippon Pharma, Eisai Pharmaceuticals, GlaxoSmithKline, Helsinn, IMClone Systems, IsisPharma, Kadmon Corporation, Kyowa Hakko Kirin, MabVax Therapeutics, Merck, Novartis, OncoGenex, OSI Pharmaceuticals, Peregrine, Pierre Fabre, Qiagen, Sanofi, Synta Pharmaceuticals, and Teva Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “The non-small cell lung cancer therapeutics market in China grew exponentially in 2014. The markets in Australia, India, and Japan are expected to witness considerable growth during the forecast period.”

According to the report, current therapies available to treat non-small cell lung cancer do not provide a permanent cure, and approaches such as non-selective cytotoxic chemotherapy tend to cause toxicity in patients.

Further, the report states that the increase in personalized therapies will lead to the fragmentation of the global non-small cell lung cancer market, thus presenting a major threat to this market.

Companies Mentioned

AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche, Pfizer, Abbvie, Aetna, Agennix, Amgen, BetaPharma, Bionumerik Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, CBT Pharma, Celldex Therapeutics, Dainippon Pharma, Eisai Pharmaceuticals, GlaxoSmithKline, Helsinn, IMClone Systems, IsisPharma, Kadmon Corporation, Kyowa Hakko Kirin, MabVax Therapeutics, Merck, Novartis, OncoGenex, OSI Pharmaceuticals, Peregrine, Pierre Fabre, Qiagen, Sanofi, Synta Pharmaceuticals, Teva Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Product profiles
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
      • Table Types of non-small cell lung cancer
      • Table Gene mutations in non-small cell lung cancer
    • Risk factors
      • Table Risk factors for non-small cell lung cancer
    • Signs and symptoms
      • Table Signs and symptoms of non-small cell lung cancer
    • Diagnosis
      • Table Tests for diagnosis of non-small cell lung cancer
    • Staging
      • Table Staging of non-small cell lung cancer
    • Treatment
      • Table Management of non-small cell lung cancer
      • Table Types of radiation therapy for non-small cell lung cancer
      • Table Photodynamic therapy uses light to actuate a drug in the body, which kills abnormal cells.Non-small cell lung cancer treatment algorithm
    • Epidemiology
  • Pipeline portfolio
    • Table Phase III pipeline molecules for non-small cell lung cancer
    • Information on pipeline candidates
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global non-small cell lung cancer therapeutics market 2014-2019 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by molecule type
    • Table Global non-small cell lung cancer therapeutics market segmentation by molecule type
    • Biologics
    • Small molecules
  • Market segmentation by route of administration
    • Table Global non-small cell lung cancer therapeutics market segmentation by route of administration
    • Oral
    • Parenteral
  • Geographical segmentation
    • Table Global non-small cell lung cancer market by geographical segmentation 2014
  • Market drivers
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
  • Vendor landscape
    • Competitive scenario
    • Market analysis 2014
      • Table F. Hoffmann-La Roche: Global YoY growth and revenue of Avastin 2011-2014 ($ millions)
      • Table F. Hoffmann-La Roche: Key takeaways
      • Table Alimta: Global YoY growth and revenue 2011-2014 ($ millions)
      • Table Gemzar: Global YoY growth and revenue 2008-2011 ($ millions)
      • Table Eli Lilly: Key takeaways
      • Table Abraxane: Global YoY growth and revenue 2011-2014 ($ millions)
      • Table Celgene: Key takeaways
      • Table Iressa: Global YoY growth and revenue 2011-2014 ($ millions)
      • Table Iressa: YoY growth and revenue in Western Europe 2011-2014 ($ millions)
      • Table Iressa: YoY growth and revenue in established ROW 2011-2014 ($ millions)
      • Table Iressa: YoY growth and revenue in emerging markets 2011-2014 ($ millions)
      • Table AstraZeneca: Key takeaways
      • Table Xalkori: Global YoY growth and revenue 2012-2014 ($ millions)
      • Table Pfizer: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: Business segmentation by revenue 2014
      • Table AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table AstraZeneca: Geographical segmentation by revenue 2014
    • Celgene
      • Table Celgene: Product segmentation by revenue 2014
      • Table Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
      • Table Celgene: Geographical segmentation by revenue 2014
    • Eli Lilly
      • Table Eli Lilly: Business segmentation by revenue 2014
      • Table Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Eli Lilly: Geographical segmentation by revenue 2014
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Business segmentation by revenue 2014
      • Table F. Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table F. Hoffmann-La Roche: Geographical segmentation by revenue 2014
    • Pfizer
      • Table Pfizer: Business segmentation by revenue 2014
      • Table Pfizer: Geographical segmentation by revenue 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report